Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S6PV
|
||||
| Former ID |
DNC003903
|
||||
| Drug Name |
VOLINANSERIN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H28FNO3
|
||||
| InChI |
InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
|
||||
| InChIKey |
HXTGXYRHXAGCFP-OAQYLSRUSA-N
|
||||
| CAS Number |
CAS 139290-65-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7979872, 11056395, 12014670, 14755501, 14804188, 39340971, 80773858, 91616570, 103275460, 103992797, 114155712, 124954269, 128128333, 134341108, 135650573, 137231458, 143057684, 144210564, 162249020, 164766144, 170500892, 176224358, 185997000, 198966064, 208265419, 215780295, 223532818, 223782286, 226970760, 241034286, 249735007, 252157845, 252159862, 252322025, 252821118
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [530045] | |
| Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [530936] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Inhibitor | [530936] | ||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP706:SIDS Susceptibility Pathways | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Potassium ChannelsWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| References | |||||
| Ref 522480 | ClinicalTrials.gov (NCT00788515) Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. U.S. National Institutes of Health. | ||||
| Ref 539159 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 185). | ||||
| Ref 530045 | Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002. Epub 2009 Mar 14.Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. | ||||
| Ref 530936 | Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. Epub 2010 Apr 24.Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.